Bristol-Myers Squibb Co
BMYToday
-1.87%
5 Days
+0.36%
1 Month
+4.16%
6 Months
+13.24%
Year to Date
+28.06%
1 Year
+48.55%
Recent
Analysis
Bristol-Myers Squibb Co Stock (BMY) Moved Up by 3.06% on Aug 21: Drivers Behind the Movement
• Bristol-Myers Squibb shares rebounded following solid quarterly financial results and guidance. • The FDA granted accelerated approval for Zenbexus in multiple myeloma treatment. • Annual revenue reached $48.19 billion with net profit of $7.05 billion.
Bristol-Myers Squibb Co Stock (BMY) Closed Down by 3.17% on Aug 20: Facts Behind the Movement
• Bristol Myers stock pulled back due to profit-taking following a multi-week rally. • Investors weighed strong operational highlights against looming patent expirations on legacy treatments. • The company reported $48.19B in annual revenue with net profit of $7.05B.
Bristol-Myers Squibb Co Stock (BMY) Moved Down by 3.10% on Aug 5: Key Drivers Unveiled
• Bristol-Myers Squibb lowered its financial outlook due to high costs replacing aging drugs. • Investors are concerned about slow adoption rates for the company's new product launches. • Federal drug pricing negotiations create valuation uncertainty and a price ceiling for shares.
AstraZeneca PLC Stock (AZN) Moved Down by 8.54% on Aug 3: Key Drivers Unveiled
• AstraZeneca Phase 3 oncology trial failed to meet its primary overall survival endpoint. • New U.S. drug price negotiations raise concerns over future profit margin compression. • Brokerage firms lowered ratings and price targets following clinical and regulatory setbacks.
Bristol-Myers Squibb Co Stock (BMY) Closed Up by 3.12% on Jul 15: Key Drivers Unveiled
• Bristol Myers Squibb rose due to positive late-stage clinical trial results. • Increased institutional inflows support the company's defensive pharmaceutical sector valuation. • Technical indicators show a breakout, with a current MACD value of 0.322.
Bristol-Myers Squibb Co Stock (BMY) Closed Down by 3.99% on Jul 14: Drivers Behind the Movement
• Bristol-Myers Squibb stock declined following disappointing data from a late-stage oncology clinical trial. • Impending patent expirations for core medications create concerns regarding long-term revenue growth sustainability. • Analysts lowered price targets amid regulatory headwinds and increased research and development spending.
Bristol-Myers Squibb Co's Score
Media Coverage
Analyst Rating
Bristol-Myers Squibb Co Technical Analysis
Technical Indicators
Summary
Moving Average
Financial Indicators
Earnings
Bristol-Myers Squibb Co Profile
Ownership
| Shareholders | Proportion |
|---|---|
| Vanguard Capital Management, LLC | 6.48% |
| BlackRock Institutional Trust Company, N.A. | 5.11% |
| State Street Investment Management (US) | 4.80% |
| Charles Schwab Investment Management, Inc. | 3.49% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 44.07% |
| Investment Advisor/Hedge Fund | 27.75% |
| Research Firm | 3.12% |
| Pension Fund | 2.89% |
Related Instruments
Popular Instruments
